Ep 82: Best of ASCO: 2026

<p>In this episode, James &amp; Sapna tease the size of ASCO and ESMO and number of simultaneous publications.</p><p>They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.</p><p>Studies discussed include:</p><ul><li>OptimUM-02 phase 2/3 trial for metastatic uveal melanoma </li><li>ADAM phase 3 trial for MCC</li><li>5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)</li><li>Pilot neoadjuvant studies (NeoReNi, NeoINR)</li><li>Time of day of infusion and immunotherapy efficacy</li></ul><p><br></p>